4,630 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Purchased by Everence Capital Management Inc.

Everence Capital Management Inc. bought a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 4,630 shares of the company’s stock, valued at approximately $203,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RVMD. GAMMA Investing LLC boosted its holdings in Revolution Medicines by 55.8% during the third quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock worth $28,000 after buying an additional 222 shares in the last quarter. Quarry LP acquired a new stake in shares of Revolution Medicines during the 3rd quarter valued at $82,000. Values First Advisors Inc. bought a new stake in shares of Revolution Medicines during the 3rd quarter worth $93,000. KBC Group NV grew its holdings in shares of Revolution Medicines by 12.9% in the 3rd quarter. KBC Group NV now owns 3,221 shares of the company’s stock worth $146,000 after acquiring an additional 368 shares during the last quarter. Finally, Amalgamated Bank raised its position in shares of Revolution Medicines by 7.4% during the second quarter. Amalgamated Bank now owns 5,272 shares of the company’s stock worth $205,000 after purchasing an additional 365 shares during the period. 94.34% of the stock is currently owned by institutional investors.

Revolution Medicines Stock Up 0.2 %

Shares of NASDAQ:RVMD opened at $44.42 on Friday. The firm has a market cap of $7.47 billion, a price-to-earnings ratio of -12.37 and a beta of 1.46. Revolution Medicines, Inc. has a 12 month low of $25.93 and a 12 month high of $62.40. The company’s fifty day simple moving average is $50.44 and its 200 day simple moving average is $46.54.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.05). During the same period in the previous year, the company earned ($0.99) EPS. Research analysts expect that Revolution Medicines, Inc. will post -3.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Barclays lifted their price target on Revolution Medicines from $54.00 to $60.00 and gave the stock an “overweight” rating in a research note on Friday, September 27th. HC Wainwright upped their price target on shares of Revolution Medicines from $64.00 to $72.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Piper Sandler lifted their price objective on shares of Revolution Medicines from $57.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Oppenheimer increased their target price on Revolution Medicines from $55.00 to $60.00 and gave the company an “outperform” rating in a report on Monday, October 28th. Finally, Wedbush reiterated an “outperform” rating and set a $70.00 price target on shares of Revolution Medicines in a report on Monday, December 2nd. Eleven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $66.25.

Insider Buying and Selling

In related news, COO Margaret A. Horn sold 4,329 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $45.40, for a total value of $196,536.60. Following the transaction, the chief operating officer now owns 127,991 shares in the company, valued at $5,810,791.40. The trade was a 3.27 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jack Anders sold 2,635 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $45.40, for a total value of $119,629.00. Following the sale, the chief financial officer now owns 96,470 shares in the company, valued at approximately $4,379,738. The trade was a 2.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 35,344 shares of company stock valued at $1,672,782 over the last 90 days. 8.00% of the stock is owned by corporate insiders.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.